Compare MIR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIR | AXSM |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.9B |
| IPO Year | N/A | 2015 |
| Metric | MIR | AXSM |
|---|---|---|
| Price | $24.53 | $148.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 20 |
| Target Price | $28.29 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 3.3M | 526.6K |
| Earning Date | 10-28-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $902,300,000.00 | $561,263,000.00 |
| Revenue This Year | $8.15 | $66.20 |
| Revenue Next Year | $19.02 | $57.56 |
| P/E Ratio | $243.04 | ★ N/A |
| Revenue Growth | 7.82 | ★ 65.83 |
| 52 Week Low | $12.00 | $75.56 |
| 52 Week High | $30.28 | $152.94 |
| Indicator | MIR | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 56.94 |
| Support Level | $24.52 | $144.00 |
| Resistance Level | $26.36 | $150.00 |
| Average True Range (ATR) | 1.03 | 4.15 |
| MACD | 0.02 | -0.73 |
| Stochastic Oscillator | 31.93 | 57.42 |
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.